{"entity":{"id":"nct05765877","kind":"trial","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Pingping Song, now recruiting.","summary":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05765877 by Pingping Song, with 26 participants planned, started 2023-03-01 and due to reach its primary completion in 2027-03. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-Small Cell Lung Cancer(NSCLC).\n\nLinked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05765877","url":"https://clinicaltrials.gov/study/NCT05765877"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["iruplinalkib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05765877","phase":"2","setting":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer: a Single-arm, Exploratory Trial","sponsor":"Pingping Song","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05765877/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/"}]}}